$8.08 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Annexon

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s pipeline is based on its platform technology addressing classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its product candidate, ANX005, is a monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases.

Stock Analysis

last close $7.69
1-mo return -41%
3-mo return -62.9%
avg daily vol. 664.32T
52-week high 38.01
52-week low 6.84
market cap. $329M
forward pe -
annual div. -
roe -36.9%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -

Subscribe now for daily local and international financial news